Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
RELT, a new member of the tumor necrosis factor receptor superfamily, is selectively expressed in hematopoietic tissues and activates transcription factor NF-kappaB
In the retatrutide Phase 2 trial, discontinuation due to adverse events ranged from 6% at 4 mg doses to 16% at 12 mg, compared with 0% for placebo [1]
A dose-response study
This helps maintain the potency and stability of the medication
US$ 24.82
US$ 22.00
US$ 27.75
US$ 23.88
US$ 21.99
US$ 27.81
US$ 28.00
US$ 26.41
US$ 29.29
US$ 28.67
US$ 24.08
